Denmark· DK-28107627726
Rimactan
A rifampicin product containing rifampicin, registered in Denmark by Epione Medicine ApS. The same ATC class is registered in 18 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Rifampicin is registered in 18 of 19 countries.
Countries holding a registration under ATC J04AB02 (rifampicin), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 10 of them publish a price we can compare per daily dose
Rifampicin · ATC J04AB02
18 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of rifampicin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), the median price runs from $0.92 in Italy to $6.35 in France — a ×6.9 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Rifampicin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- FR France$6.35
- CH Switzerland$4.70
- IT Italy$0.92
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- RIFAMPICIN
- Manufacturer
- Epione Medicine ApS
- Country
- Denmark (DK)
- ATC code
- J04AB02
- ATC class
- Rifampicin
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28107627726
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
444 interactions on record for rifampicin.
Graded by severity as the source publishes them — 144 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rifampicin · interactions on record
444 records
- 144 severe
- 173 moderate
- 14 minor
- 39 info
Most severe, free to view
- RolapitantA04AD14severe
- NaloxegolA06AH03severe
- NaldemedineA06AH05severe
- EluxadolineA07DA06severe
74 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under J04AB02
Rifampicin, as other registers publish it.
- CzechiaBENEMICIN"Tarchomińskie Zakłady Farmaceutyczne ""Polfa"" S.A., Varšava"
- CzechiaBENEMICIN"Tarchomińskie Zakłady Farmaceutyczne ""Polfa"" S.A., Varšava"
- NorwayEremfatEsteve Pharmaceuticals GmbH
- NorwayEremfatRiemser Pharma GmbH
- NorwayEremfatRiemser Pharma GmbH
- NorwayEremfatRiemser Pharma GmbH
- GermanyEremfatEsteve Pharmaceuticals Gmbh
- NorwayEremfatEsteve
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b1872e35-8a51-4088-839b-252ca5741cf2 GET /v1/drugs/b1872e35-8a51-4088-839b-252ca5741cf2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "kapsler, hårde",
"source": "dkma",
"strength": "300 mg",
"auth_role": "DKMA",
"dk_drugid": "28107627726",
"substance": "RIFAMPICIN",
"auth_procedure": "Par-Imp",
"in_medicinpriser": true,
"registration_date_serial": "46168"
}See everything about rifampicin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.